Investigator/Institution	Patient Population	Interventions	Status of Patient Accrual
D. Alberts/Univ. of Arizona	Prior sporadic adenoma	Ursodeoxycholic acid vs. placebo	Closed
M. Bertagnolli/Multicenter	Prior sporadic adenoma	Celecoxib vs. placebo	Closed
Women’s Health Initiative/National Institutes of Health	Postmenopausal women	Low-fat diet vs. calcium + vitamin D vs. HRT vs. placebo	Closed
J. Burn/CAPP-1, Univ. of Newcastle	Prephenotypic FAP	Aspirin vs. resistant starch vs. both vs. placebo	Closed
uk-CAP/Cancer Research U.K.	Prior sporadic adenoma	Aspirin vs. folate vs. both vs. placebo	Closed
P. Lance/Univ. of Arizona	Prior sporadic adenoma	Celecoxib vs. selenium vs. both vs. placebo	Open selenium vs. placebo only
J. Baron/Dartmouth Univ.	Prior sporadic adenoma	Aspirin ± folate vs. placebo; also, folate arm is ongoing	Closed
H. Berkel/Hipple Cancer Research Center	Prior sporadic adenoma	Piroxicam vs. calcium carbonate vs. both vs. placebo	Closed
E. Giovannucci/Harvard	Prior sporadic adenoma	Folate vs. placebo	Closed
J. Burn/CAPP-2, Univ. of Newcastle	HNPCC patients or mutation carriers	Aspirin vs. resistant starch vs. both vs. placebo	Closed

FAP = familial adenomatous polyposis; ACF = aberrant crypt foci; HRT = hormone replacement therapy; CAPP = Concerted Action Polyposis Prevention Study; uk-CAP = United Kingdom Colorectal Adenoma Prevention Study; HNPCC = hereditary nonpolyposis colorectal cancer.

Also see Umar et al.[24]

References

24. Umar A, Viner JL, Richmond E, et al.: Chemoprevention of colorectal carcinogenesis. Int J Clin Oncol 7 (1): 2-26, 2002.  [PUBMED Abstract]